Skip to Content
Merck
All Photos(1)

Documents

549835

Sigma-Aldrich

2,4,6-Tris(dimethylamino)-1,3,5-triazine

96%

Synonym(s):

Altretamine, Hexamethylmelamine

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C9H18N6
CAS Number:
645-05-6
Molecular Weight:
210.28
EC Number:
211-428-4
MDL number:
MFCD00549245
UNSPSC Code:
12352100
PubChem Substance ID:
24874728
NACRES:
NA.22

Assay

96%

mp

171-175 °C (lit.)

SMILES string

CN(C)c1nc(nc(n1)N(C)C)N(C)C

InChI

1S/C9H18N6/c1-13(2)7-10-8(14(3)4)12-9(11-7)15(5)6/h1-6H3

InChI key

UUVWYPNAQBNQJQ-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

2,4,6-Tris(dimethylamino)-1,3,5-triazine exhibits antitumor activity.

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H302,H315,H319,H335

Hazard Classifications

Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Target Organs

Respiratory system

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Triazines and related products. Part 26. Synthesis and chemistry of bicyclic analogues of the antitumour drug 2, 4, 6-tris (dimethylamino)-1, 3, 5-triazine (hexamethylmelamine).
Langdon SP, et al.
Journal of the Chemical Society. Perkin Transactions 1, 993-998 (1984)
Maurie Markman et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24(9), 1454-1458 (2006-03-22)
A previous report suggested the nadir serum CA-125 level within the group of patients with ovarian cancer who achieved normalization of CA-125 accurately defined the risk of relapse. Using similar CA-125 subgroups, we sought to determine if the baseline CA-125
P Sørensen et al.
Gynecologic oncology, 81(1), 58-62 (2001-03-30)
The purpose of this phase II study was to evaluate on an intent-to-treat basis the activity and toxicity of single-agent vinorelbine (VRL) as second-line chemotherapy of patients with platinum-resistant ovarian cancer. Platinum-resistant disease was defined as disease refractory to or
Medication sheets for patients. Oral chemotherapy.
Clinical journal of oncology nursing, 7(6 Suppl), 40-72 (2004-01-07)
Lessons from a time capsule: evolution, not revolution, in therapy for advanced non-small-cell lung cancer.
Mark R Green
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26(19), 3112-3113 (2008-07-02)
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service